Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment

Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment

Decitabine (DAC) is clinically used to treat myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Our genome-wide CRISPR-dCas9 activation screen using MDS-derived AML cells indicates that mitotic regulation is critical for DAC resistance. DAC strongly induces abnormal mitosis (abscission...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Tomohiro Yabushita, Takumi Chinen, Atsuya Nishiyama, Shuhei Asada, Ruka Shimura, Tomoya Isobe, Keita Yamamoto, Naru Sato, Yutaka Enomoto, Yosuke Tanaka, Tomofusa Fukuyama, Hitoshi Satoh, Keiko Kato, Kaori Saitoh, Takamasa Ishikawa, Tomoyoshi Soga, Yasuhito Nannya, Tatsuo Fukagawa, Makoto Nakanishi, Daiju Kitagawa, Toshio Kitamura, Susumu Goyama
Natura: Artigo
Lingua:inglese
Pubblicazione: 2023
Accesso online:https://doi.org/10.1016/j.celrep.2023.113098
https://www.cell.com/article/S2211124723011099/pdf
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Accesso online

https://doi.org/10.1016/j.celrep.2023.113098
https://www.cell.com/article/S2211124723011099/pdf

Documenti analoghi